Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rigel Pharmaceuticals (RIGL)

Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 499,510
  • Shares Outstanding, K 18,473
  • Annual Sales, $ 294,280 K
  • Annual Income, $ 367,020 K
  • EBIT $ 125 M
  • EBITDA $ 127 M
  • 60-Month Beta 1.10
  • Price/Sales 1.61
  • Price/Cash Flow 3.83
  • Price/Book 1.20

Options Overview Details

View History
  • Implied Volatility 86.80% (-17.22%)
  • Historical Volatility 47.38%
  • IV Percentile 65%
  • IV Rank 40.21%
  • IV High 142.67% on 03/24/26
  • IV Low 49.22% on 08/26/25
  • Expected Move (DTE 16) 2.68 (9.90%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 90
  • Volume Avg (30-Day) 165
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 2,627
  • Open Int (30-Day) 4,237
  • Expected Range 24.36 to 29.72

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $0.86
  • Number of Estimates 2
  • High Estimate $0.95
  • Low Estimate $0.76
  • Prior Year $0.63
  • Growth Rate Est. (year over year) +36.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.95 +8.38%
on 03/19/26
35.00 -22.74%
on 03/03/26
-7.70 (-22.16%)
since 02/27/26
3-Month
24.95 +8.38%
on 03/19/26
49.10 -44.93%
on 01/07/26
-16.97 (-38.56%)
since 12/26/25
52-Week
15.50 +74.45%
on 04/09/25
52.24 -48.24%
on 11/28/25
+9.16 (+51.23%)
since 03/28/25

Most Recent Stories

More News
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology

Pralsetinib induced robust and durable responses with a manageable safety profile, reinforcing the benefits of selective RET inhibitors in treating RET fusion-positive NSCLC

RIGL : 27.04 (+5.13%)
Rigel: Q4 Earnings Snapshot

Rigel: Q4 Earnings Snapshot

RIGL : 27.04 (+5.13%)
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif. , March 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 27.04 (+5.13%)
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update

SOUTH SAN FRANCISCO, Calif. , Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results...

RIGL : 27.04 (+5.13%)
Rigel Appoints Michael P. Miller to the Board of Directors

SOUTH SAN FRANCISCO, Calif. , Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller...

RIGL : 27.04 (+5.13%)
Rigel Provides Business Update and 2026 Outlook

SOUTH SAN FRANCISCO, Calif. , Jan. 12, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 27.04 (+5.13%)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , Jan. 9, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc....

RIGL : 27.04 (+5.13%)
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 27.04 (+5.13%)
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif. , Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 27.04 (+5.13%)
Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif. , Nov. 26, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today...

RIGL : 27.04 (+5.13%)

Business Summary

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory diseases, cancer and viral diseases. Its goal is to file one new investigative new drug application in a significant indication each year....

See More

Key Turning Points

3rd Resistance Point 28.28
2nd Resistance Point 27.72
1st Resistance Point 27.38
Last Price 27.04
1st Support Level 26.49
2nd Support Level 25.93
3rd Support Level 25.59

See More

52-Week High 52.24
Fibonacci 61.8% 38.21
Fibonacci 50% 33.87
Fibonacci 38.2% 29.53
Last Price 27.04
52-Week Low 15.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.